Fig. 5: PI3K signaling pathway is involved in GAL1-driven increase of P-gp expression. | Cell Death & Disease

Fig. 5: PI3K signaling pathway is involved in GAL1-driven increase of P-gp expression.

From: Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression

Fig. 5

P-gp expression analyzed by western blot (upper panel) and densitometric analysis (lower panel) in HepG2-GAL1 and control cells in the presence of signaling pathway inhibitors. Cells were pre-incubated for 24 h with PD98059 (PD, inhibitor of MEK), wortmannin (Wort, inhibitor of PI3K), and H89 (inhibitor of PKA). DMSO and saline solution were used as vehicles for PD98059 and wortmannin, and H89, respectively. β-tubulin was used as loading control. Results are expressed as the mean of relative P-gp expression in the presence of the indicated inhibitor with respect to the corresponding vehicle-treated cell lines (100%) ± SEM (n = 4). **p < 0.01 with respect to DMSO-treated HepG2-GAL1 cells.

Back to article page